Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | SCN1A | P35498 | 1/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10326582 | 1.00 | CYP2D6 (0.62) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL10327263 | 1.00 | CYP2D6 (0.62) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL3236521 | 0.95 | CYP2D6 (0.56) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL10326938 | 0.90 | CYP2C19 (0.49) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL12295122 | 0.90 | CYP2C19 (0.49) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL10326936 | 0.90 | CYP2C19 (0.49) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL12295125 | 0.90 | KDM4E (0.51) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL10326804 | 0.90 | KDM4E (0.51) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL10326597 | 0.90 | KDM4E (0.51) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL12295126 | 0.86 | CYP1A2 (0.51) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107213-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND APPLICATIONS OFANTITUMOR THEREOF | ZHEJIANG UNIVERSITY (CN) | 2017-04-20 | — | — | US | disclosed |
| EP-2438989-B1 | USE OF ASYMMETRIC HYDROGENATION CATALYST | TAKASAGO PERFUMERY CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-9040738-B2 | Intermediate compounds of tamiflu, methods of preparation and uses thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2015-05-26 | — | — | US | disclosed |
| US-20140221662-A1 | INTERMEDIATE COMPOUNDS OF TAMIFLU, METHODS OF PREPARATION AND USES THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2014-08-07 | — | — | US | disclosed |
| US-8217204-B2 | Catalyst for asymmetric hydrogenation | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | H1-0, H1-5, ADH5 | CYP2D6 1125/4885CYP1A2 1183/4885CYP2C19 2363/4885 |
| US-20170107213-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND APPLICATIONS OFANTITUMOR THEREOF | AKT1, RELA, AKT3 | CYP2D6 1245/4885CYP1A2 2205/4885CYP2C19 2072/4885 |
| US-20140221662-A1 | INTERMEDIATE COMPOUNDS OF TAMIFLU, METHODS OF PREPARATION AND USES THEREOF | NNMT, FLT3, TPMT | CYP2D6 155/4885CYP1A2 112/4885CYP2C19 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.